SCHEMBL25921185

SCHEMBL25921185

O=C(Nc1ccc(CNc2ccccc2)cc1)c1ccc2c(c1)CCCS2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.46
▸ HDAC1 Q13547 2/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ NCOR2 Q9Y618 1/20 0.46
▸ HIF1A Q16665 3/20 0.44
▸ MAPK14 Q16539 1/20 0.43
▸ SCD O00767 1/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124166 0.91 HDAC8 (0.48) MAPTHDAC1HDAC3HDAC2NCOR2
SCHEMBL24125238 0.87 NPC1 (0.43) MAPTHDAC1NPC1RAB9ASMN1; SMN2
SCHEMBL8460319 0.83 MEN1 (0.52) MAPTNCOR2NPC1RAB9ASMN1; SMN2
SCHEMBL9147195 0.82 MEN1 (0.51) MAPTNCOR2MAPK14NPC1RAB9A
SCHEMBL24124184 0.82 HDAC1 (0.47) MAPTHDAC1HDAC3HDAC2NCOR2
SCHEMBL24125078 0.81 MAPT (0.43) MAPTHDAC1NCOR2MAPK14NPC1
SCHEMBL24125019 0.81 NPC1 (0.42) MAPTHDAC1NCOR2MAPK14NPC1
SCHEMBL24124316 0.80 GPR27 (0.59) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL24124786 0.79 KMT2A (0.46) MAPTNCOR2NPC1RAB9ASMN1; SMN2
SCHEMBL24124243 0.77 NPC1 (0.50) MAPTMAPK14NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 MAPT 4492/4885HDAC1 898/4885HDAC3 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback